Rockville, Maryland – October 15, 2026 — The global rare disease research genomics services market is projected to grow from USD 587.7 million in 2026 to USD 1,222.6 million by 2036, according to the latest market report published by Fact.MR. The industry is anticipated to expand at a compound annual growth rate (CAGR) of 7.6% over the forecast period, reflecting rising demand for advanced genomic analysis, improved interpretation of genetic variants, and research services that help investigate rare and inherited conditions.

Get detailed market forecasts, competitive benchmarking, and pricing trends: 

KEY MARKET TAKEAWAYS

• Market Valuation: USD 587.7 million in 2026, rising to USD 1,222.6 million by 2036.
• Growth Rate: Expanding at a CAGR of 7.6% from 2026 to 2036.
• Leading Segment: Whole Genome Sequencing accounts for 25.0% of the market by service type in 2026.
• Fastest-Growing Country: Germany leads the selected country markets with a projected CAGR of 10.3%.
• Core Growth Driver: Demand for comprehensive genomic analysis that helps reduce repeated testing and investigate previously unresolved rare-disease cases.

INDUSTRY SHIFTS & MARKET DYNAMICS

Rare disease research increasingly requires a combination of genomic sequencing, patient phenotype assessment, and detailed genetic interpretation. Whole Genome Sequencing is expected to hold a 25.0% share of the market by service type in 2026, as its broader coverage can help researchers investigate genetic changes that narrower testing approaches may miss. Next-Generation Sequencing is also projected to account for 25.0% of the market by technology. Pharmaceutical and biotechnology companies represent another important customer group, with an estimated 30.0% share by end user in 2026, supported by demand for drug-target discovery, patient cohort identification, and clinical research planning.

The industry nevertheless faces constraints involving research funding, reimbursement for broad genomic testing, and shortages of clinical genetics and bioinformatics professionals. Uncertain genetic findings can also require additional laboratory investigation before they inform research decisions. Restrictions on data sharing across institutions and countries may limit comparisons involving small patient populations. Service providers that combine reliable sequencing with careful variant interpretation, documented data quality, and follow-up analysis are positioned to address these operational challenges. The market is expected to create an additional USD 634.9 million in value between 2026 and 2036.

REGIONAL MARKET SUMMARY

Fact.MR projects the following country-level growth rates for the rare disease research genomics services market between 2026 and 2036.

Germany is projected to lead the selected markets as university hospitals and specialist referral centers support complex rare-disease investigations. Brazil's growth outlook reflects expanding genomics research activity and opportunities to study diverse genetic populations. The United States benefits from established specialist laboratories and research funding, while South Korea's hospital networks support research involving detailed patient records. In the United Kingdom, coordinated genomic programs and laboratory infrastructure are expected to contribute to continued demand.

ANALYST INSIGHTS

"Rare-disease research clients judge genetic testing providers by how often they help solve difficult cases and guide research decisions. Partners that review patient symptoms, family history and larger DNA changes are likely to see wider use. Providers can add further value by checking unresolved cases again when new medical evidence becomes available," stated Shambhu Nath Jha, Senior Analyst at Fact.MR.

The market outlook highlights opportunities for genomics service providers that extend beyond sequencing alone. Research sponsors may increasingly require integrated analysis, repeat evaluation of unresolved cases, and bioinformatics support to interpret complex findings. These capabilities can help pharmaceutical companies refine research cohorts and investigate potential therapeutic targets. Through 2036, the ability to deliver consistent results and connect genetic evidence with actionable research findings will remain important to market development.

Unlock 360° insights for strategic decision making and investment planning: 

FREQUENTLY ASKED QUESTIONS

Q: What is the projected size of the rare disease research genomics services market by 2036?

A: The market is estimated at USD 587.7 million in 2026 and is projected to reach USD 1,222.6 million by 2036, growing at a CAGR of 7.6%.

Q: Which segment holds the leading market share?

A: Whole Genome Sequencing is projected to lead by service type, accounting for 25.0% of the market in 2026.

Q: Which country exhibits the highest growth rate?

A: Germany is projected to lead the selected country markets with a CAGR of 10.3% between 2026 and 2036.

Q: What factors are driving market growth?

A: Demand is supported by the need for comprehensive genomic analysis, investigation of unresolved rare-disease cases, improved variant interpretation, and genomic research for pharmaceutical development.

Q: What challenges could restrict market expansion?

A: Funding limitations, shortages of specialized professionals, uncertain genetic findings requiring additional validation, and restrictions on cross-border data sharing may constrain adoption.

Explore More Related Studies Published by Fact.MR Research

Familial Hypercholesterolemia Treatment Market

Smart Implants Market

About Fact.MR

Fact.MR is a market research and consulting firm providing syndicated research, customized research, investment research, and market intelligence across a broad range of industries. Its research coverage includes food and beverage, healthcare, pharmaceuticals, biotechnology, consumer products, chemicals and materials, technology, industrial goods, and packaging.

Fact.MR provides market intelligence designed to help organizations understand market dynamics, emerging opportunities, competitive developments, and changing industry requirements.

Media Contact

Fact.MR
Email: sales@factmr.com
Phone: +1 (628) 251-1583
Website: www.factmr.com